Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives $34.42 Consensus PT from Brokerages

Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the eleven brokerages that are covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation and ten have assigned a buy recommendation to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $34.42.

A number of research firms have recently issued reports on SNDX. StockNews.com raised Syndax Pharmaceuticals to a "sell" rating in a research report on Friday, January 19th. Citigroup decreased their price objective on shares of Syndax Pharmaceuticals from $32.00 to $30.00 and set a "buy" rating on the stock in a report on Thursday, May 9th. Scotiabank cut shares of Syndax Pharmaceuticals from a "sector outperform" rating to a "sector perform" rating and cut their target price for the stock from $36.00 to $23.00 in a research note on Wednesday, January 31st. JPMorgan Chase & Co. upped their price target on shares of Syndax Pharmaceuticals from $31.00 to $34.00 and gave the company an "overweight" rating in a research note on Wednesday, March 20th. Finally, Stifel Nicolaus boosted their price objective on Syndax Pharmaceuticals from $39.00 to $40.00 and gave the stock a "buy" rating in a report on Thursday, May 9th.

Hedge Funds Weigh In On Syndax Pharmaceuticals

A number of hedge funds have recently modified their holdings of the business. CWM LLC lifted its stake in shares of Syndax Pharmaceuticals by 415.3% in the fourth quarter. CWM LLC now owns 1,685 shares of the company's stock worth $36,000 after acquiring an additional 1,358 shares during the period. MeadowBrook Investment Advisors LLC acquired a new stake in shares of Syndax Pharmaceuticals during the fourth quarter worth $37,000. Quadrant Capital Group LLC boosted its position in Syndax Pharmaceuticals by 158.3% during the fourth quarter. Quadrant Capital Group LLC now owns 2,441 shares of the company's stock valued at $53,000 after acquiring an additional 1,496 shares during the last quarter. Annandale Capital LLC acquired a new stake in Syndax Pharmaceuticals during the 3rd quarter worth about $67,000. Finally, Signaturefd LLC boosted its position in shares of Syndax Pharmaceuticals by 2,874.6% during the 4th quarter. Signaturefd LLC now owns 3,748 shares of the company's stock valued at $81,000 after purchasing an additional 3,622 shares in the last quarter.

Syndax Pharmaceuticals Stock Down 3.0 %

Shares of SNDX stock traded down $0.63 during trading on Friday, reaching $20.29. The company's stock had a trading volume of 957,497 shares, compared to its average volume of 1,105,034. Syndax Pharmaceuticals has a one year low of $11.22 and a one year high of $25.34. The business has a fifty day moving average price of $22.29 and a 200-day moving average price of $20.50. The company has a market cap of $1.72 billion, a price-to-earnings ratio of -6.30 and a beta of 1.01.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last posted its quarterly earnings results on Wednesday, May 8th. The company reported ($0.85) earnings per share for the quarter, topping the consensus estimate of ($0.96) by $0.11. During the same period last year, the business posted ($0.59) EPS. Research analysts anticipate that Syndax Pharmaceuticals will post -3.58 EPS for the current year.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).